Neuropharmacology

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Retrieved on: 
Wednesday, March 6, 2024

Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.

Key Points: 
  • Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
  • The Company’s industry-leading GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system.
  • The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.
  • The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology.

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Retrieved on: 
Wednesday, February 28, 2024

Dr. Pfost noted, “AxoSim embodies the entrepreneur’s sweet spot--when market need, technological innovation, timing and team all align. The growing prevalence of neurological diseases places enormous burdens on patients, their families and society. Yet despite billions in investment, neurology R&D continues to disappoint. AxoSim’s transformational approach addresses a key contributor to these failures—the lack of relevant disease models—by providing functional human data from its microphysiological system (MPS) organoid technologies early in the process. AxoSim aims to become an industry leader in helping to deliver urgently needed new drugs and I welcome the opportunity to contribute to its success.”

Key Points: 
  • Dr. Pfost and Dr. Weiner have decades of experience in building successful biotechnology companies spanning therapeutics, diagnostics and life science tools and technologies.
  • “Our recent acquisition of a third platform technology positions AxoSim for growth, and we are fortunate to have these two talented industry veterans assuming key leadership roles,” said Lowry Curley, PhD, co-founder and Chief Executive Officer of AxoSim.
  • “Dale and Dave bring successful track records in building life sciences businesses, with broad and complementary skill sets.
  • Dale’s work in life science tools and venture finance is highly relevant, as is Dave’s expertise in leading neurological drug discovery and clinical development.

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.

QPS Holdings, LLC divests its Neuropharmacology Business Unit

Retrieved on: 
Thursday, November 30, 2023

Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO.

Key Points: 
  • Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO.
  • QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders.
  • QPS Neuropharmacology is based in a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees.
  • We believe that the neuropharmacology unit will be strengthened and continue to grow as part of the Scantox organization” says Ben Chien, President and CEO of QPS Holdings, LLC.

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

Retrieved on: 
Monday, November 20, 2023

Dr. Fava is a world leader in the field of depression and clinical psychopharmacology.

Key Points: 
  • Dr. Fava is a world leader in the field of depression and clinical psychopharmacology.
  • Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university.
  • He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014.
  • Professor Knudsen received her medical and doctoral degrees from the University of Copenhagen, Denmark and completed her training in neurology.

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

Retrieved on: 
Monday, December 4, 2023

BALTIMORE, Dec. 4, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic and neuropsychiatric disorders, has released new data from artificial intelligence (AI) simulations that show that, compared to plant-based medical marijuana, there may be significant potential advantages to the therapeutic potential of MIRA1a, such as its potential to offer a superior anti-anxiety treatment, increased cognition and without the increased appetite associated with THC.

Key Points: 
  • The simulations on MIRA1a were conducted in conjunction with the Company's strategic collaboration with InSilicoTrials , a company specializing in leveraging AI and simulations to enhance drug and medical device development.
  • In silico analysis is a computational technique that uses AI to predict the interaction between drugs and their targets.
  • The simulations suggest that MIRA1a's agonistic action on the 5-HT1a receptor aligns with established anxiolytic properties in medications like Buspirone and certain SSRIs.
  • "In the groundbreaking field of neuropharmacology, artificial intelligence and machine learnings have ushered in a new era of drug discovery and analysis," said Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals.

Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023

Retrieved on: 
Monday, November 6, 2023

HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C.

Key Points: 
  • HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C.
  • The latest advancements from the Company’s Data Sciences International (DSI) preclinical business expand the reach of DSI’s industry-leading, GLP-compliant Ponemah™ preclinical data management platform.
  • These advancements include DSI’s new SoHo™ implantable telemetry solution for small animal models and its VivaMARS™ high-capacity behavior monitoring system.
  • Representatives will be present during exhibit hours from Sunday November 12, 2023 through Wednesday November 15, 2023 from 9.30 a.m. to 5.00 p.m. EST.

EEG Analysis and Animal Behavior in CNS Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 4, 2023

TORONTO, Oct. 4, 2023 /PRNewswire-PRWeb/ -- EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and compounds will exhibit clinical efficacy early in preclinical development.

Key Points: 
  • In this free webinar, gain insights into electroencephalography (EEG) analysis as physiological endpoints to facilitate drug discovery, lead optimization or candidate compound selection as well as to serve for go/no go decisions.
  • The featured speaker will share case studies of EEG-based signatures in correlation with animal behavior which potentially may validate the EEG as endpoints for a set of translatable biomarkers bridging preclinical and clinical programs.
  • EEG-based signatures represent promising preclinical screens to quickly determine CNS penetration, drug-target engagement, evidence of efficacy, pharmacokinetic/pharmacodynamic profile, CNS safety and toxicity and pro-convulsant risk.
  • Join this webinar to gain insights into EEG analysis as physiological endpoints to facilitate drug discovery for CNS diseases.

Evecxia Therapeutics Announces CEO Transition

Retrieved on: 
Thursday, September 14, 2023

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.

Key Points: 
  • Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.
  • Dr. Jacobsen succeeds Joseph Patti, Ph.D., who has stepped down from his role as President and CEO of Evecxia to pursue other interests.
  • While a scientist at Duke University, he co-founded Evecxia with the late James B Duke Professor, Dr. Marc Caron.
  • “I am excited to be leading Evecxia at this pivotal time in the Company’s history,” said Dr. Jacobsen.

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Retrieved on: 
Monday, July 24, 2023

The data were published in Neuropharmacology by Addex and The Scripps Research Institute.

Key Points: 
  • The data were published in Neuropharmacology by Addex and The Scripps Research Institute.
  • “In the United States, opioid abuse and overdose have reached epidemic proportions, with oxycodone being the most abused prescription opioid.
  • In previous research, this approach has successfully been used in nicotine, cocaine and alcohol models,” said Dr. Robert Lütjens, Head of Discovery – Biology at Addex.
  • “Demonstrating the wide potential of mGlu2 PAMs, an Addex discovered drug candidate, ADX71149, is being evaluated in a phase 2 clinical study as a potential treatment for epilepsy by our partner Janssen.”